The APR provides aggregated results COVID-19-related disruptions negatively affected sales in the fourth quarter of 2020, which benefited year-over-year sales growth. Fiscal Year 2022 Annual Comprehensive Financial Report (ACFR), Fiscal Year 2021 Annual Comprehensive Financial Report (ACFR), Fiscal Year 2022 Popular Annual Financial Report, Fiscal Year 2021 Popular Annual Financial Report, Fiscal Year 2020 Popular Annual Financial Report, Fiscal Year 2021 Projects Expenditure Report. Separate reports must be submitted for each Reduction Endorsement Fishery. St. Louis District Office . A phased resupply of ZERBAXA was initiated in the fourth quarter of 2021, which the company expects to continue in 2022. Higher sales of companion animal products were primarily driven by the BRAVECTO (fluralaner) parasiticide line of products, as well as vaccines. Calculate differential runoff for 15-year 20-min (St. Louis County) or 20-year 20-min (St. Louis City) storm. related to the receipt of milestone payments for an out-licensed product. Home; Shareholder Letter; Financial Review. The non-GAAP range excludes acquisition- and divestiture-related costs, costs related to restructuring programs as well as income and losses from investments in equity securities. The Office of the Superintendent of Public Instruction awarded Washington Achievement Awards to: Salem Description of stormwater management facilities proposed, with BMP Drainage Area Map (see BMP Drainage Area Map instructions) 3. (908) 740-103 Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Merck & Co., Inc., Rahway, NJ, USA is known as MSD outside of the United States and Canada. Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: (Loss) Income from Discontinued Operations. All rights reserved. , It noted a range of possible measures including that MSD should report a RAHWAY, N.J., Feb. 2, 2023 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022. The company advanced its broad pipeline, closed the acquisition of Acceleron Pharma Inc. (Acceleron) and delivered initial shipments of molnupiravir, an investigational oral antiviral COVID-19 treatment. All such filings are available free of charge. The increase in SG&A expenses in both periods was partially offset by a $100 million charge in the fourth quarter of 2020 for a Merck Foundation contribution. **Alliance revenue for this product represents Mercks share of profits, which are product sales net of cost of sales and commercialization costs. WebMSD Annual Report ANNUAL REPORT TO THE NEW YORK STATE CIVIL SERVICE COMMISSION 2014 Reporting Agency :CUNY A. A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows. The ACFR enables a reader to gain a reasonable understanding of the Districts financial activities while also fulfilling the Districts regulatory requirements. Institutional investors and analysts can participate in the call by dialing (833) 353-0277 or (469) 886-1947 and using ID code number 1774118. WebAdvisory Group (WEAG) report. Investor Contacts: Add to Calendar, Icons / 16 / Microphone The increase for both periods primarily reflects lower acquisition- and divestiture-related costs, driven in part by an impairment charge related to ZERBAXA recorded in the fourth quarter of 2020, as well as the favorable effects of product mix and lower inventory write-offs. View all locations and contact information, Asia Pacific (other than Japan and China). MSDs fourth-quarter and full-year 2021 results reflect continued strong business momentum and operational strength. FSA requested LIA to conduct follow-up on member LIs efforts in line with the report. Web TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File No. The effective tax rate for the fourth quarter reflects the impact of the lower full-year rate as well as foreign tax credits. $59.3 billion 2022 Revenues (by geographic area, including pharmaceutical and animal health revenue) 2022 R&D expenses $13.5 billion Products MSD is a global The increase primarily reflects higher compensation and benefit costs, partially offset by the reimbursement of a portion of molnupiravir R&D costs from Ridgeback. The decrease in both periods primarily reflects the impacts from molnupiravir, which has a lower gross margin due to profit sharing with Ridgeback, and higher manufacturing costs. Merck expects full-year 2022 GAAP EPS to be between $5.76 and $5.91. Research and development (R&D) expenses were $3.1 billion in the fourth quarter of 2021 compared with $5.8 billion in the fourth quarter of 2020. and chief executive officer. St. Louis, MO 63103-2555. Partially offsetting the gross margin improvement in both periods were the impacts from molnupiravir, which has a lower gross margin due to profit sharing with Ridgeback, as well as higher manufacturing costs. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. Web202223 Season Annual Report INSTRUCTIONS: It is very important that each crab buyer report this information under the correct RegisteredCrab Receiver (RCR) Permit number under which the fish tickets were created. JUNE 23023 , 2. Merck shares profits equally with its partner, Ridgeback, which is reflected in cost of sales. WebANNUAL REPORT TO THE NEW YORK STATE CIVIL SERVICE COMMISSION 2016 Reporting Agency : CUNY A. The Popular Annual Financial Report (PAFR) now serves as MSDs charter required written report to the City and the County. Income (Loss) from Continuing Operations Before Taxes, Net Income (Loss) from Continuing Operations, Less: Net Income Attributable to Noncontrolling Interests. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Acquisition- and divestiture-related costs. The decline in R&D expenses for the full year was partially offset by higher clinical development spending and increased investment in discovery research and early drug development, net of the reimbursement of a portion of molnupiravir R&D costs from Ridgeback. 2022 This website of Merck & Co., Inc., Rahway, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. Full-year sales growth was primarily driven by companion animal products, led by the BRAVECTO line of products and vaccines. Web2022 Annual Report PDF Format Download (opens in new window) PDF 6.37 MB Interactive Annual Report PDF Format Download (opens in new window) PDF 9.10 MB 2023 Proxy Statement PDF Format Download (opens in new window) PDF 2.15 MB Formerly Utilized Sites Remedial Action Program These percentages are calculated using only the victims where race was collected. MSD is required to conduct an annual audit by an independent audit firm. Share this article. MSD publishes 2021/2022 Environmental, Social & Governance (ESG) Progress Report. February 3, 2022. Worldwide Non-GAAP EPS excludes acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities and certain other items. For over 130 years, Merck, known as MSD outside the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the worlds most challenging diseases in pursuit of our mission to save and improve lives. Private Securities Litigation Reform Act of 1995. Access videos, logos, photos, and infographics. is a testament to the profound impact our medicines and vaccines are having on patients globally," said Robert M. Davis, chairman water qualityflowsplitter device), Proprietary BMP Cut-Sheets and O&M Manuals, General Stormwater Management Facilities Description, BMP Type Specific Inspection Checklists & Description. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the companys 2020 Annual Report on Form 10-K and the companys other filings with the Securities and Exchange Commission (SEC) available at the SECs Internet site (www.sec.gov). This full year guidance includes expected sales of $5 billion to $6 billion from molnupiravir. Robert M. Davis, chairman and chief executive officer, View the list of executive committee members, Our pipeline shows our relentless pursuit of the next breakthrough. A reconciliation of anticipated 2022 GAAP EPS to non-GAAP EPS and the items excluded from non-GAAP EPS are provided in the table below. WebMerck & Co., Inc. Investor Event at ASCO 2023. 2350 Market Street Financials. , The full year effective tax rate reflects a more favorable mix of income and expense than previously anticipated. In particular, reports were received on Leavers Process, Information Security Controls and Accounts Receivable. MSD has made significant progress on permit activities ahead of schedule for Permit Year 1. These statements are based upon the current beliefs and expectations of the companys management and are subject to significant risks and uncertainties. MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2022. WebChild Poverty in New Zealand 2021 report. The goal of the independent audit is to Gross margin was 71.4% for the fourth quarter of 2021 compared to 54.1% for the fourth quarter of 2020. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the companys ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the companys patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so. Burns were the most common injury to hands and fingers. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Also contributing to growth in hospital acute care were higher sales of DIFICID (fidaxomicin), a macrolide antibacterial drug for treatment of Clostridioides difficile-associated diarrhea in adults and pediatric patients aged 6 months and older, which increased 89% to $60 million due to higher demand in the U.S. This report offers transparency and disclosure of the Districts financial health which is verified as accurate in all material respects by the audit firm. Other revenues in full-year 2021 include $185 million. from The effective income tax rate was 2.2% for the fourth quarter of 2021 and 11.0% for the full year of 2021. (215) 407-353 Management believes that providing this information enhances investors understanding of the companys results as it permits investors to understand how management assesses performance. Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a result of acquisitions, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Each year, the District prepares an Enterprise-wide Annual Comprehensive Financial Report ( ACFR ). Net Income (Loss) Attributable to Merck & Co., Inc. Molnupiravir sales were $952 million in the fourth quarter of 2021, primarily consisting of sales in the U.S., the U.K. and Japan. Full-year 2021 pharmaceutical sales increased 17% to $42.8 billion. View the full release here: https://www.businesswire.com/news/home/20220203005264/en/, Our business achieved strong revenue and earnings growth this quarter and for the full year. Part One Wide range of detailed findings, with a special focus on the use of child-specific hardship indicators to paint a picture of life below the line. Download the full 2021 report - Child Poverty in New Zealand, Download the full 2021 report - Child Poverty in New Zealand as a Word document, Download the shortened version of Part One of the 2021 full report, Download the shortened version of Part One of the full 2021 report as a Word document, the demographics of child poverty, with breakdowns by different household characteristics, what it means in practice day-to-day for children who are identified as poor by one or more of the CPRA measures using child-specific indicators available for the first time in HES 2018-19, how New Zealand children are faring compared with their European counterparts. Animal Health sales totaled $1.3 billion for the fourth quarter of 2021, an increase of 8% compared with the fourth quarter of 2020, reflecting growth across geographies and species. (617) 216-602 , Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2021. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA. Acquisition- and Commissioners or Personnel Officer 1. To protect the publics health, safety, and water environment by responsibly providing wastewater and stormwater management. This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Non-GAAP net income that excludes certain items1,2*, Non-GAAP EPS that excludes certain items2*. In addition, senior managements annual compensation is derived in part using non-GAAP pretax income. MSDs Q2 2022 results deliver robust sales growth and important clinical advancements. If such circumstances were toRead more, Additionally, estimates are used inRead more, Pension and other postretirement benefitRead more, In November 2022, Merck's BoardRead more, Research and Development Research andRead more, The change was primarily drivenRead more, These disruptions could increase inRead more, Restructuring costs also include assetRead more, The increase was primarily dueRead more, Executive Summary Merck's 2022 resultsRead more, The increase in working capitalRead more, Also included in R&D expensesRead more, Cautionary Factors That May AffectRead more, Restructuring Costs In 2019, MerckRead more, Separation costs associated with manufacturing-relatedRead more, Worldwide sales of Isentress/Isentress HD,Read more, The related intangible asset thatRead more, Higher sales of Bridion, Welireg,Read more, In addition, if collection ofRead more, Vaccines Combined worldwide sales ofRead more, Higher sales of hospital acuteRead more, Global sales of Keytruda grewRead more, The Company anticipates all ofRead more, Also excluded from the determinationRead more, The decrease in these expensesRead more, However, difficulties in reducing thoseRead more, The increase in cash providedRead more, Selling, General and Administrative Selling,Read more, For exposures in developing countryRead more, Sales of companion animal productsRead more, The sales increase was primarilyRead more, The Company's material cash requirementsRead more, Additionally, the tax rate fromRead more, Worldwide sales of Dificid, forRead more, One must carefully consider anyRead more, Keytruda sales growth in internationalRead more, Other (Income) Expense, Net OtherRead more, In an asset acquisition, acquiredRead more, Merck's revenue in 2022 benefitedRead more, Estimates are used when accountingRead more, The amortization catch-up is calculatedRead more, Impairments are recognized in operatingRead more, Revenue Recognition Recognition of revenueRead more, Also contributing to revenue growthRead more, Since non-GAAP income and non-GAAPRead more, Taxes on Income The effectiveRead more, Worldwide sales were $59.3 billionRead more, Research and development expenses inRead more, Worldwide sales of Prevymis, aRead more, The Company reassesses its benefitRead more, The Company's senior unsecured euro-denominatedRead more, In January 2023, Merck acquiredRead more, As discussed above, COVID-19-related disruptionsRead more, Assets acquired and liabilities assumedRead more, Non-GAAP Income and Non-GAAP EPSRead more, Net gain/loss amounts, which primarilyRead more, Operating Results Sales Worldwide salesRead more, When accruing termination costs, theRead more, Contingent Milestone Payments - TheRead more, Analysis of Liquidity and CapitalRead more, This measurement assumes that aRead more, Interest Rate Risk Management TheRead more, Additionally, the Company currently hasRead more, The fair values of intangibleRead more, The Company anticipates making modestRead more, In 2021, COVID-19-related disruptions resultedRead more, Merck's capital allocation priorities areRead more, The Company evaluates IPR&D forRead more, The Company expects foreseeable liquidityRead more, Worldwide sales of Pneumovax 23,Read more, Animal Health Segment Sales ofRead more, Exercised an option to obtainRead more, Operating expenses in 2021 reflectRead more, Entered into a collaboration withRead more, Other acquired intangible assets (excludingRead more, Application of the following accountingRead more, R&D expenses are comprised ofRead more, Additionally, the Company considers factorsRead more, Restructuring Costs Non-GAAP income andRead more, As discussed below, COVID-19-related disruptionsRead more, Amounts allocated to acquired IPR&DRead more, The amounts are capitalized andRead more, For impairment testing purposes, theRead more, Generally, the Company will combineRead more, The fair values of identifiableRead more, A reconciliation between GAAP financialRead more, Additionally, the Company has liabilitiesRead more, The Company recorded aggregate pretaxRead more, The portfolio's equity weighting isRead more, Additionally, if the IPR&D programsRead more, Accordingly, the Company may beRead more, Non-GAAP income and non-GAAP EPSRead more, Description of Merck's Business MerckRead more, Merck and Moderna will collaborateRead more, The majority of the Company'sRead more, The estimate of the provisionRead more, Merck Co., Inc. provided additional information to their SEC Filing as exhibits, Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not, Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news, Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q, Remove data columns and navigations in order to see much more filing content and tables in one view, Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q, Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis, Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity, See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years, Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings, View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. In addition, MSD is required to make a yearly written report to the Mayor and the Board of Aldermen of the City of St. Louis, and to the County Executive and the County Council of St. Louis County. This is highlighted by Figure Seven, which shows the average composition of total income for different family types. Non-GAAP EPS that excludes items listed below2, Non-GAAP net income that excludes items listed below1,2. Meet the leaders who guide our purpose to use the power of leading-edge science to save and improve lives around the world. 3. COVID-19-related disruptions negatively affected sales in 2021, but to a lesser extent than in 2020, which benefited year-over-year sales growth. 2023 Wastewater & Stormwater Rate Proposal, System Maintenance, Inspection, Rehabilitation, & Replacement, Capital Improvement & Replacement Program (CIRP), Capital Construction Pre-Qualification Process, Capital Construction Current Bid Opportunities, Rules, Regulations, & Design Requirements, Capital Improvement & Replacement Program (CIRP) Funding. Water Quality/Channel Protection/Flood Protection MEP Calculation Tool (as applicable), 4. The increase in both periods was largely driven by higher acquisition- and divestiture- related costs, as well as higher administrative costs, including compensation and benefit costs, and increased promotional expenses in support of the companys growth pillars. Financial information presented in this release reflects Mercks results on a continuing operations basis, which excludes Organon & Co. that was spun-off on June 2, 2021. WebThis annual report provides an overview of total weekly income for main benefit clients as at the end of April 2023. We aspire to be the premier research-intensive biopharmaceutical company in the world and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. Income From Continuing Operations Before Taxes. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more, Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports, Consolidated Balance Sheet (Parenthetical), Consolidated Statement Of Cash Flows (Parenthetical), Consolidated Statement Of Comprehensive Income, Consolidated Statement Of Equity (Parenthetical), Acquisitions, Research Collaborations And Licensing Agreements, Acquisitions, Research Collaborations And Licensing Agreements (Tables), Acquisitions, Research Collaborations And Licensing Agreements - Estimated Fair Value Of Assets Acquired And Liabilities Assumed (Details), Acquisitions, Research Collaborations And Licensing Agreements - Narrative (Details), Collaborative Arrangements - Financial Information (Details), Collaborative Arrangements - Narrative (Details), Contingencies And Environmental Liabilities, Contingencies And Environmental Liabilities (Details), Earnings Per Share - Calculations Of Earnings Per Share (Details), Financial Instruments - Effect Of Net Investment Hedges (Details), Financial Instruments - Fair Value Of Derivatives Segregated Between Those Derivatives That Are Designated As Hedging Instruments And Those That Are Not Designated As Hedging Instruments (Details), Financial Instruments - Fair Value Of Hedges (Details), Financial Instruments - Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Details), Financial Instruments - Income Statement Effects On Derivatives Not Designated As Hedging Instruments (Details), Financial Instruments - Information About Changes In Liabilities For Contingent Consideration (Details), Financial Instruments - Information On Debt And Equity Securities (Details), Financial Instruments - Information On Derivative Positions Subject To Master Netting Arrangements As If They Were Presented On A Net Basis (Details), Financial Instruments - Location And Pretax (Gains) Or Loss Amounts For Derivatives (Details), Financial Instruments - Narrative (Details), Goodwill And Other Intangibles - Goodwill Activity By Segment (Details), Goodwill And Other Intangibles - Narrative (Details), Goodwill And Other Intangibles - Other Intangibles (Details), Loans Payable, Long-Term Debt And Leases (Tables), Loans Payable, Long-Term Debt And Leases - Balance Sheet Information (Details), Loans Payable, Long-Term Debt And Leases - Long-Term Debt (Details), Loans Payable, Long-Term Debt And Leases - Maturity Schedule (Details), Loans Payable, Long-Term Debt And Leases - Narrative (Details), Other (Income) Expense, Net - Narrative (Details), Other (Income) Expense, Net - Schedule Of Other (Income) Expense, Net (Details), Other Comprehensive Income (Loss) (Details), Other Comprehensive Income (Loss) (Tables), Pension And Other Postretirement Benefit Plans, Pension And Other Postretirement Benefit Plans (Tables), Pension And Other Postretirement Benefit Plans - Accumulated And Projected Benefit Obligation In Excess Of Plan Assets (Details), Pension And Other Postretirement Benefit Plans - Components Of Net Periodic Benefit Cost (Details), Pension And Other Postretirement Benefit Plans - Components Of Other Comprehensive Income (Details), Pension And Other Postretirement Benefit Plans - Fair Values Of Other Postretirement Benefit Plan Assets (Details), Pension And Other Postretirement Benefit Plans - Fair Values Of Pension Plan Assets (Details), Pension And Other Postretirement Benefit Plans - Narrative (Details), Pension And Other Postretirement Benefit Plans - Obligation And Funded Status (Details), Pension And Other Postretirement Benefit Plans - Summary Of Changes In Fair Value Of Company's Level 3 Pension Plan Assets (Details), Pension And Other Postretirement Benefit Plans - Summary Of Expected Benefit Payments (Details), Pension And Other Postretirement Benefit Plans - Summary Of Health Care Cost Trend Rate Assumptions For Other Postretirement Benefit Plans (Details), Pension And Other Postretirement Benefit Plans - Summary Of Weighted Average Assumptions Used In Determining Pension Plan And U.S. Pension And Other Postretirement Benefit Plan Information (Details), Restructuring - Activities By Program (Details), Restructuring - Charges Activities By Type Of Cost (Details), Segment Reporting - Consolidated Revenues By Geographic Area (Details), Segment Reporting - Equity Loss From Affiliates And Depreciation Included In Segment Profits (Details), Segment Reporting - Property, Plant And Equipment, Net By Geographic Area (Details), Segment Reporting - Reconciliation Of Segment Profits To Income Before Taxes (Details), Segment Reporting - Sales Of Company's Products (Details), Share-Based Compensation Plans - Additional Information Pertaining To Stock Option Plans (Details), Share-Based Compensation Plans - Assumptions Used To Determine Weighted-Average Fair Value Of Options Granted (Details), Share-Based Compensation Plans - Narrative (Details), Share-Based Compensation Plans - Summary Of Information Relative To Stock Option Plan Activity (Details), Share-Based Compensation Plans - Summary Of Nonvested Rsu And Psu Activity (Details), Spin-Off Of Organon &Amp; Co. - Income From Discontinued Operations, Net Of Taxes And Amounts Attributable To Noncontrolling Interests (Details), Spin-Off Of Organon &Amp; Co. - Narrative (Details), Summary Of Accounting Policies (Policies), Taxes On Income - Deferred Income Taxes (Details), Taxes On Income - Income Before Taxes (Details), Taxes On Income - Income Tax Authority (Details), Taxes On Income - Reconciliation Between Effective Tax Rate And Us Statutory Rate (Details), Taxes On Income - Taxes On Income (Details), Taxes On Income - Unrecognized Tax Benefits (Details), Exhibit 21: Subsidaries Of The Registrant, Exhibit 23: Consents Of Experts And Counsel, Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification, Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification, https://last10k.com/sec-filings/mrk/0001628280-23-005061.htm, Fourth-Quarter and Full-Year 2022 Results Reflect Sustained Strong Revenue Growth, Fourth-Quarter 2022 GAAP EPS From Continuing Operations Was $1.18; Fourth-Quarter 2022 Non-GAAP EPS Was $1.62, KEYTRUDA Sales Grew 22% to $20.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27%, GARDASIL/GARDASIL 9 Sales Grew 22% to $6.9 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 27%, In 2022, Augmented Pipeline Through Strategic Business Development,Including Acquisition of Imago and Key Agreements With Moderna,
Importance Of Ethics In Writing,
Articles M
msd annual report pdf
